Waters Corporation $WAT Shares Bought by ABN Amro Investment Solutions

ABN Amro Investment Solutions grew its stake in shares of Waters Corporation (NYSE:WAT) by 125.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,000 shares of the medical instruments supplier’s stock after buying an additional 2,224 shares during the period. ABN Amro Investment Solutions’ holdings in Waters were worth $1,191,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in WAT. Geode Capital Management LLC raised its stake in shares of Waters by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier’s stock valued at $602,921,000 after acquiring an additional 8,590 shares during the period. Invesco Ltd. boosted its position in Waters by 32.3% during the 3rd quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier’s stock worth $441,446,000 after purchasing an additional 359,596 shares during the period. Veritas Asset Management LLP increased its holdings in Waters by 112.3% in the 4th quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier’s stock valued at $471,447,000 after purchasing an additional 656,436 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Waters by 17.0% in the 1st quarter. Principal Financial Group Inc. now owns 1,019,289 shares of the medical instruments supplier’s stock valued at $303,556,000 after purchasing an additional 148,320 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Waters by 60.8% in the first quarter. Dimensional Fund Advisors LP now owns 814,716 shares of the medical instruments supplier’s stock valued at $242,599,000 after purchasing an additional 307,941 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Waters Trading Down 2.1%

Waters stock opened at $374.49 on Friday. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $414.15. The firm’s 50-day moving average is $365.23 and its 200-day moving average is $346.13. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79. The company has a market cap of $36.77 billion, a P/E ratio of 47.59, a PEG ratio of 2.27 and a beta of 1.20.

Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the firm earned $2.25 EPS. The company’s revenue for the quarter was up 91.4% compared to the same quarter last year. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. On average, equities analysts expect that Waters Corporation will post 14.51 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on WAT. Wall Street Zen downgraded shares of Waters from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Sanford C. Bernstein initiated coverage on shares of Waters in a research report on Friday, June 26th. They set an “outperform” rating and a $435.00 target price on the stock. Evercore restated an “outperform” rating and issued a $410.00 target price on shares of Waters in a research note on Monday, July 6th. Wells Fargo & Company raised their price target on shares of Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Waters from $330.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Waters has an average rating of “Moderate Buy” and a consensus price target of $401.60.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.